# KSD-101 in Patients With EBV-associated Hematological Malignancies

> **NCT07525024** · — · NOT_YET_RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 80 (estimated)

## Conditions studied

- EBV Associated Lymphoid Neoplasms

## Interventions

- **BIOLOGICAL:** Autologous dendritic cell vaccine

## Key facts

- **NCT ID:** NCT07525024
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2031-03
- **Final completion:** 2031-03
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07525024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07525024, "KSD-101 in Patients With EBV-associated Hematological Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07525024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*